Even if MYL no longer felt it had a viable Copax, they may have decided that it was in their interest to continue to pursue these patents just for the PR value to offset the negative press on EPI.
It would make for an uncomfortable relationship if MNTA had to sue MYL if the latter actually get their Copaxone approved.
Market Data 
Markets 
AI
